IL301948B2 - Anti-cd3 antibody formulations - Google Patents
Anti-cd3 antibody formulationsInfo
- Publication number
- IL301948B2 IL301948B2 IL301948A IL30194823A IL301948B2 IL 301948 B2 IL301948 B2 IL 301948B2 IL 301948 A IL301948 A IL 301948A IL 30194823 A IL30194823 A IL 30194823A IL 301948 B2 IL301948 B2 IL 301948B2
- Authority
- IL
- Israel
- Prior art keywords
- formulation
- antibody
- formulations
- trehalose
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380652P | 2016-08-29 | 2016-08-29 | |
| PCT/US2017/049211 WO2018044948A1 (en) | 2016-08-29 | 2017-08-29 | Anti-cd3 antibody formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL301948A IL301948A (en) | 2023-06-01 |
| IL301948B1 IL301948B1 (en) | 2024-05-01 |
| IL301948B2 true IL301948B2 (en) | 2024-09-01 |
Family
ID=59858782
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264502A IL264502B2 (en) | 2016-08-29 | 2017-08-29 | Anti-cd3 antibody formulations |
| IL301948A IL301948B2 (en) | 2016-08-29 | 2017-08-29 | Anti-cd3 antibody formulations |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264502A IL264502B2 (en) | 2016-08-29 | 2017-08-29 | Anti-cd3 antibody formulations |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10688186B2 (enExample) |
| EP (2) | EP3504241B1 (enExample) |
| JP (3) | JP7057360B2 (enExample) |
| CN (2) | CN109843920B (enExample) |
| AU (2) | AU2017319318B2 (enExample) |
| CA (1) | CA3032596A1 (enExample) |
| DK (1) | DK3504241T3 (enExample) |
| ES (1) | ES2986900T3 (enExample) |
| IL (2) | IL264502B2 (enExample) |
| WO (1) | WO2018044948A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2986900T3 (es) | 2016-08-29 | 2024-11-13 | Tiziana Life Sciences Plc | Formulaciones de anticuerpos anti-cd3 |
| EP3634478A4 (en) * | 2017-06-06 | 2021-03-24 | The Brigham and Women's Hospital, Inc. | MICROGLIAL ACTIVATION INHIBITION METHODS |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2020073087A1 (en) * | 2018-10-09 | 2020-04-16 | Monash University | Combination therapy for treatment and prevention of autoimmune and inflammatory diseases |
| AU2019373663A1 (en) | 2018-10-31 | 2021-04-08 | Tiziana Life Sciences Plc | Composition and methods of treating inflammatory and autoimmune diseases |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| EP4017526A1 (en) | 2019-08-20 | 2022-06-29 | Precision BioSciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
| WO2021180821A2 (en) * | 2020-03-10 | 2021-09-16 | Tiziana Life Sciences Plc | Compositions of il-6/il-6r antibodies and methods of use thereof |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
| IL299744A (en) * | 2020-07-30 | 2023-03-01 | Tiziana Life Sciences Plc | Antibodies to CD-3 for the treatment of the corona virus |
| PH12023550213A1 (en) * | 2020-07-31 | 2023-10-16 | Glaxosmithkline Ip Dev Ltd | Antigen binding protein |
| EP4323404A1 (en) * | 2021-04-16 | 2024-02-21 | Tiziana Life Sciences PLC | Subcutaneous administration of antibodies for the treatment of disease |
| JP2025515781A (ja) * | 2022-05-13 | 2025-05-20 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | フォラルマブの経鼻製剤 |
| CN119948056A (zh) * | 2022-07-27 | 2025-05-06 | 塞尔德克斯医疗公司 | 抗kit抗体制剂和方法 |
| CN120112292A (zh) | 2022-09-09 | 2025-06-06 | 爱杜西亚药品有限公司 | 包含抗-cd3抗体及cxcr3拮抗剂的药物组合 |
| EP4662230A1 (en) | 2023-02-08 | 2025-12-17 | ImmunOs Therapeutics AG | Fusion proteins of ss2 microglobulin, hla heavy chain polypeptides, and inhibitor of cd47-sirpa |
| TW202448505A (zh) | 2023-03-01 | 2024-12-16 | 美商普泛森生技公司 | 用於治療第1型糖尿病的方法及組成物 |
| WO2024190892A1 (ja) * | 2023-03-16 | 2024-09-19 | 小野薬品工業株式会社 | 抗体製剤 |
| JP7548475B1 (ja) * | 2023-03-16 | 2024-09-10 | 小野薬品工業株式会社 | 抗体製剤 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007033230A2 (en) * | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-cd3 antibody formulations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030235583A1 (en) | 2002-06-14 | 2003-12-25 | Jeppe Sturis | Combined use of a modulator of CD3 and a beta cell resting compound |
| US20040037826A1 (en) | 2002-06-14 | 2004-02-26 | Michelsen Birgitte Koch | Combined use of a modulator of CD3 and a GLP-1 compound |
| WO2005048935A2 (en) * | 2003-11-14 | 2005-06-02 | Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| EP2225275A4 (en) * | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| CN102164960A (zh) * | 2008-09-26 | 2011-08-24 | 罗氏格黎卡特股份公司 | 双特异性抗-egfr/抗-igf-1r抗体 |
| MX2011013722A (es) * | 2009-06-18 | 2012-05-08 | Wyeth Llc | Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños. |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| US20120269826A1 (en) * | 2009-10-20 | 2012-10-25 | Mckee Charlotte | Anti-cd3 antibody dosing in autoimmune disease |
| JP2013508391A (ja) * | 2009-10-20 | 2013-03-07 | グラクソ グループ リミテッド | 体重増加を予防するために抗cd3抗体を使用する方法 |
| WO2011080209A2 (en) * | 2009-12-29 | 2011-07-07 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
| WO2012098238A1 (en) * | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| ES2986900T3 (es) | 2016-08-29 | 2024-11-13 | Tiziana Life Sciences Plc | Formulaciones de anticuerpos anti-cd3 |
-
2017
- 2017-08-29 ES ES17765519T patent/ES2986900T3/es active Active
- 2017-08-29 IL IL264502A patent/IL264502B2/en unknown
- 2017-08-29 CN CN201780052970.8A patent/CN109843920B/zh active Active
- 2017-08-29 CN CN202211674110.7A patent/CN116617387A/zh active Pending
- 2017-08-29 AU AU2017319318A patent/AU2017319318B2/en active Active
- 2017-08-29 IL IL301948A patent/IL301948B2/en unknown
- 2017-08-29 US US15/690,192 patent/US10688186B2/en active Active
- 2017-08-29 EP EP17765519.8A patent/EP3504241B1/en active Active
- 2017-08-29 CA CA3032596A patent/CA3032596A1/en active Pending
- 2017-08-29 EP EP24175798.8A patent/EP4406554A3/en active Pending
- 2017-08-29 DK DK17765519.8T patent/DK3504241T3/da active
- 2017-08-29 WO PCT/US2017/049211 patent/WO2018044948A1/en not_active Ceased
- 2017-08-29 JP JP2019531579A patent/JP7057360B2/ja active Active
-
2020
- 2020-05-18 US US16/876,839 patent/US20210000957A1/en not_active Abandoned
-
2022
- 2022-04-07 JP JP2022063973A patent/JP7461401B2/ja active Active
-
2024
- 2024-03-22 JP JP2024046063A patent/JP2024075713A/ja active Pending
- 2024-12-16 AU AU2024278457A patent/AU2024278457A1/en active Pending
-
2025
- 2025-02-07 US US19/048,132 patent/US20250228946A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007033230A2 (en) * | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-cd3 antibody formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| DK3504241T3 (da) | 2024-08-19 |
| IL301948A (en) | 2023-06-01 |
| EP3504241B1 (en) | 2024-05-15 |
| IL264502B1 (en) | 2023-05-01 |
| AU2024278457A1 (en) | 2025-01-09 |
| CN109843920B (zh) | 2023-01-13 |
| CA3032596A1 (en) | 2018-03-08 |
| IL301948B1 (en) | 2024-05-01 |
| JP7057360B2 (ja) | 2022-04-19 |
| CN116617387A (zh) | 2023-08-22 |
| JP2024075713A (ja) | 2024-06-04 |
| JP2022082757A (ja) | 2022-06-02 |
| IL264502A (en) | 2019-02-28 |
| AU2017319318B2 (en) | 2024-09-19 |
| AU2017319318A1 (en) | 2019-02-21 |
| US10688186B2 (en) | 2020-06-23 |
| US20180177880A1 (en) | 2018-06-28 |
| JP2019526627A (ja) | 2019-09-19 |
| EP4406554A3 (en) | 2024-10-30 |
| CN109843920A (zh) | 2019-06-04 |
| EP4406554A2 (en) | 2024-07-31 |
| IL264502B2 (en) | 2023-09-01 |
| EP3504241A1 (en) | 2019-07-03 |
| US20250228946A1 (en) | 2025-07-17 |
| WO2018044948A1 (en) | 2018-03-08 |
| US20210000957A1 (en) | 2021-01-07 |
| JP7461401B2 (ja) | 2024-04-03 |
| ES2986900T3 (es) | 2024-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250228946A1 (en) | Anti-cd3 antibody formulations | |
| JP6541581B2 (ja) | 低濃度抗体製剤 | |
| EP1933868A2 (en) | Anti-cd3 antibody formulations | |
| US20220008533A1 (en) | Composition and methods of treating inflammatory and autoimmune diseases | |
| WO2014066468A1 (en) | Stable, low viscosity antibody formulation | |
| CA3178853A1 (en) | Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof | |
| TW202128133A (zh) | 重組全人源抗tigit單株抗體製劑及其製備方法和用途 | |
| HK40011182B (en) | Anti-cd3 antibody formulations | |
| HK40011182A (en) | Anti-cd3 antibody formulations | |
| WO2024171082A1 (en) | Stable protein compositions of anti-pd1 antibody | |
| HK1233918A (en) | Stable, low viscosity antibody formulation |